Compare REPL & WIW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | REPL | WIW |
|---|---|---|
| Founded | 2015 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 454.6M | 512.1M |
| IPO Year | 2018 | N/A |
| Metric | REPL | WIW |
|---|---|---|
| Price | $15.65 | $8.34 |
| Analyst Decision | Hold | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $5.67 | N/A |
| AVG Volume (30 Days) | ★ 5.6M | 256.5K |
| Earning Date | 05-21-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 11.14% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.50 | $8.25 |
| 52 Week High | $16.15 | $9.03 |
| Indicator | REPL | WIW |
|---|---|---|
| Relative Strength Index (RSI) | 64.26 | 48.36 |
| Support Level | $8.79 | $8.34 |
| Resistance Level | N/A | $8.60 |
| Average True Range (ATR) | 1.05 | 0.04 |
| MACD | 0.07 | 0.00 |
| Stochastic Oscillator | 92.27 | 35.00 |
Replimune Group Inc is a clinical-stage biotechnology company committed to applying its expertise in the field of oncolytic immunotherapy to transform the lives of cancer patients through novel oncolytic immunotherapies. Its proprietary oncolytic immunotherapy product candidates are designed and intended to maximally activate the immune system against cancer. Oncolytic immunotherapy is an emerging drug class. The proprietary RPx platform is based on a novel, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added that are intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. It operates in single segment of developing oncolytic immunotherapies for the treatment of cancer.
Western Asset Inflation-Linked Opportunities and Income Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to provide current income. Capital appreciation, when consistent with current income, is a secondary investment objective. The fund operates as a single operating segment, which is an investment portfolio.